14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.87 $1.55 Wednesday, 1st May 2024 ADAP stock ended at $1.21. This is 1.68% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 7.76% from a day low at $1.16 to a day high of $1.25.
90 days $0.87 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
Mar 28, 2022 $2.08 $2.13 $2.01 $2.05 460 500
Mar 25, 2022 $2.22 $2.22 $2.06 $2.10 455 600
Mar 24, 2022 $2.17 $2.24 $2.12 $2.19 463 800
Mar 23, 2022 $2.24 $2.26 $2.15 $2.16 510 900
Mar 22, 2022 $2.13 $2.26 $2.08 $2.25 586 696
Mar 21, 2022 $2.18 $2.19 $2.10 $2.13 1 012 195
Mar 18, 2022 $2.06 $2.24 $2.04 $2.18 1 332 013
Mar 17, 2022 $1.82 $2.11 $1.80 $2.11 1 844 200
Mar 16, 2022 $1.76 $1.87 $1.76 $1.84 1 907 400
Mar 15, 2022 $1.80 $1.85 $1.69 $1.73 1 327 500
Mar 14, 2022 $1.83 $1.90 $1.77 $1.82 1 046 600
Mar 11, 2022 $1.90 $1.93 $1.81 $1.82 1 135 100
Mar 10, 2022 $1.94 $1.94 $1.86 $1.89 825 700
Mar 09, 2022 $2.00 $2.04 $1.92 $1.94 1 735 900
Mar 08, 2022 $1.99 $2.03 $1.90 $1.95 2 753 900
Mar 07, 2022 $2.08 $2.16 $1.90 $1.95 7 938 500
Mar 04, 2022 $2.14 $2.19 $2.02 $2.05 1 253 900
Mar 03, 2022 $2.35 $2.36 $2.16 $2.19 3 319 300
Mar 02, 2022 $2.40 $2.45 $2.28 $2.32 2 034 400
Mar 01, 2022 $2.60 $2.62 $2.39 $2.41 3 378 200
Feb 28, 2022 $2.64 $2.77 $2.58 $2.60 641 200
Feb 25, 2022 $2.73 $2.74 $2.60 $2.69 375 100
Feb 24, 2022 $2.45 $2.74 $2.42 $2.69 788 300
Feb 23, 2022 $2.82 $2.83 $2.65 $2.67 320 100
Feb 22, 2022 $2.78 $2.93 $2.76 $2.79 471 400
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT